STING1 and neoplasm: Clinically, in a patient with recurrent, metastatic breast ACC, dazostinag combined with pembrolizumab achieved a partial response with approximately 70% tumor reduction, suggesting that STING pathway activation can reverse antigen presentation defects and restore ICI sensitivity in such tumors (NCT04420884) [99].